<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>International Cancer of the Pancreas Screening (CAPS) Consortium consensus on screening for pancreatic cancer in patients with increased risk for familial pancreatic cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">International Cancer of the Pancreas Screening (CAPS) Consortium consensus on screening for pancreatic cancer in patients with increased risk for familial pancreatic cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">International Cancer of the Pancreas Screening (CAPS) Consortium consensus on screening for pancreatic cancer in patients with increased risk for familial pancreatic cancer</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Who?</td> </tr> <tr> <td class="indent1"> <ul> <li>All patients with Peutz-Jeghers syndrome (carriers of a germline <em>LKB1</em>/<em>STK11</em> gene mutation) </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>All carriers of a germline <em>CDKN2A</em> mutation </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Carriers of a germline <em>BRCA2</em>, <em>BRCA1</em>, <em>PALB2</em>, <em>ATM</em>, <em>MLH1</em>, <em>MSH2</em>, or <em>MSH6</em> gene mutation with at least 1 affected first-degree blood relative </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Individuals who have at least 1 first-degree relative with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer (familial pancreatic cancer kindred) </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_single">When (at what age)?</td> </tr> <tr> <td class="indent1"> <ul> <li>Age to initiate surveillance depends on an individual's gene mutation status and family history </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading" style="list-style-type: disc;"> <li>Familial pancreatic cancer kindred (without a known germline mutation): <ul style="list-style-type: circle;"> <li>Start at age 50 or 55*, or 10 years younger than the youngest affected blood relative </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading" style="list-style-type: disc;"> <li>Mutation carriers: <ul style="list-style-type: circle;"> <li>For <em>CDKN2A</em><sup>¶</sup> and Peutz-Jeghers syndrome, start at age 40 </li> <li>For <em>BRCA2</em>, <em>ATM</em>, <em>PALB2</em>, <em>BRCA1</em>, and <em>MLH1</em>/<em>MSH2</em>, start at age 45 or 50, or 10 years younger than the youngest affected blood relative </li> </ul> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>There is no consensus on the age to end surveillance </li> </ul> </td> </tr> <tr class="divider_top"> <td class="subtitle1_single">How?</td> </tr> <tr> <td class="indent1"><strong>At baseline</strong></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>MRI/MRCP + EUS + fasting blood glucose and/or HbA1c </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>During follow-up</strong></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Alternate MRI/MRCP and EUS (no consensus on if and how to alternate) </li> <li>Routinely test fasting blood glucose and/or HbA1c </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>On indication</strong></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Serum CA 19-9: <ul> <li>If concerning features on imaging </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>EUS-FNA only for: <ul> <li>Solid lesions of ≥5 mm </li> <li>Cystic lesions with worrisome features </li> <li>Asymptomatic MPD strictures (with or without mass) </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>CT only for: <ul> <li>Solid lesions, regardless of size </li> <li>Asymptomatic MPD strictures of unknown etiology (without mass) </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Intervals and surgery</strong></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>12 months: <ul> <li>If no abnormalities or only nonconcerning abnormalities (eg, pancreatic cysts without worrisome features) </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>3 or 6 months: <ul> <li>If concerning abnormalities for which immediate surgery is not indicated (refer to UpToDate text) </li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Surgery: <ul> <li>If positive FNA and/or a high suspicion of malignancy on imaging (refer to UpToDate text) </li> </ul> </li> <li style="list-style-type: none;"><em>When surgery is indicated, perform an oncologic radical resection at a specialty center</em> </li> </ul> </td> </tr> <tr> <td class="indent1"><strong>Goals</strong></td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>The goal of surveillance is to detect and treat the following pathologic lesions: <ul> <li>Stage I pancreatic cancer, confined to the pancreas, resected with negative margins </li> <li>Pancreatic cancer precursor lesions with high-grade dysplasia (PanIN or IPMN) </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><em>LKB1</em>: liver kinase B1; <em>STK11</em>: serine/threonine kinase 11; <em>CDKN2A</em>: cyclin-dependent kinase inhibitor 2A; <em>BRCA</em>: breast cancer associated; <em>PALB2</em>: partner and localizer of <em>BRCA2</em>; <em>ATM</em>: ataxia telangiectasia mutated; <em>MLH1</em>: mutL homolog 1; <em>MSH</em>: mutS homolog; MRI/MRCP: magnetic resonance imaging/magnetic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; HbA1c: hemoglobin A1c; CA 19-9: carbohydrate antigen 19-9; FNA: fine-needle aspiration; MPD: main pancreatic duct; CT: computed tomography; PanIN: pancreatic intraepithelial neoplasia; IPMN: intraductal papillary mucinous neoplasm.<br/>* Consensus as to when to start surveillance was not reached.<br/>¶ Literature-based recommendation.</div><div class="graphic_reference">Reproduced with permission from: Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69(1):7-17. Copyright © 2020 BMJ Publishing Group Ltd.</div><div id="graphicVersion">Graphic 107902 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
